Waters Corporation (WAT) 2024 Earnings Analysis
Waters Corporation2024 Earnings Analysis
77/100
Waters Corporation entered FY2024 with a business model defined more by operating discipline than by financial engineering, and the filing for the period ended December 31, 2024 still points in that direction: $2.96B of revenue, $638M of net income, and $620M of free cash flow. LC-MS Platform, BD Biosciences Transaction, and LC-MS Standard remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. The combination of 59.4% gross margin and 27.9% operating margin suggests LC-MS Platform was still pricing and executing well. What matters most from here is whether the existing economics can hold through the next turn in demand.
Core Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Earnings Quality
Gross Margin matters here because gross Margin matters here because gross Margin matters here because gross margin of 59.4% reflects the disclosed instrument and recurring revenue (consumables and service) mix.
A better way to read operating margin is to notice that a better way to read operating margin is to notice that a better way to read operating margin is to notice that the 27.9% operating margin reflects the disclosed instrument installed base economics — recurring-revenue contribution from consumables and service.
CF / Net Income is not just a statistic here; it shows that CF / Net Income is not just a statistic here; it shows that CF / Net Income is not just a statistic here; it shows that OCF of $762M is 1.19x net income of $638M — reflecting depreciation per the cash-flow reconciliation.
The earnings file is readable because LC-MS Platform keeps margins and cash pointing in the same direction: 59.4% gross margin, 27.9% operating margin, and 1.19x cash conversion. The mix around LC-MS Platform and BD Biosciences Transaction kept the economics intact even while end-market conditions stayed uneven. 27.9% operating margin and 4.8% capex intensity are a coherent pair once LC-MS Platform is put at the center of the business model. LC-MS Platform is still turning accounting profit into cash at a healthy rate, which makes the FY2024 result easier to trust.
Moat Strength
The practical value of lc-ms standard is that the practical value of lc-ms standard is that the practical value of lc-ms standard is that synapt platforms as described in the product line) systems are widely-deployed in pharma analytical labs per public industry communications.
Per SEC and company filings, validated-Method Lock-In helps explain why validated-Method Lock-In helps explain why validated-Method Lock-In helps explain why pharma-validated analytical methods using Waters instruments create regulatory-inertia switching cost (FDA / EMA-validated method change requires revalidation per public regulatory practice).
Read recurring service revenue as evidence that read recurring service revenue as evidence that read recurring service revenue as evidence that recurring revenue (chemistry consumables + service contracts) contributes approximately half of revenue mix as described in the revenue-decomposition.
A better way to frame the moat question is to start with LC-MS Platform and BD Biosciences Transaction. The picture gets stronger once LC-MS Standard and Validated-Method Lock-In are added, because they make the advantage broader than one single product cycle. The numbers back the qualitative case because LC-MS Platform still shows up in 34.9% ROE and solid cash generation at the same time. The conclusion is not invincibility; it is that the next rival still has to beat LC-MS Platform inside a real workflow advantage.
Capital Allocation
Free Cash Flow tells you that free Cash Flow tells you that free Cash Flow tells you that FCF of $620M (OCF $762M minus capex $142M) supports the disclosed share-repurchase program.
The reason to focus on share repurchase is that the reason to focus on share repurchase is that the reason to focus on share repurchase is that waters returns FCF principally through share repurchase as described in the buyback authorization.
Net Debt Position matters in capital allocation because net Debt Position matters in capital allocation because net Debt Position matters in capital allocation because long-term debt of $1.63B against $325M cash equals net debt of $1.31B as described in the capital-structure footnote.
The allocation question begins with $620M of free cash flow and with how much cash LC-MS Platform leaves behind, not with headline EPS. The low capex burden at 4.8% of revenue gives management more freedom over buybacks, dividends, M&A, or balance-sheet repair around LC-MS Platform. Cash at $325M does not erase debt at $1.63B, so the balance sheet still leans on a durable cash engine. Both the dividend and repurchases remain in play, so capital allocation around LC-MS Platform is balanced rather than one-dimensional.
Key Risks
Pharma Capex Cycle matters as a risk because pharma Capex Cycle matters as a risk because pharma Capex Cycle matters as a risk because waters' instrument-revenue tracks pharma and biotech R&D capital budget cycles as described in the customer-base communications (current biotech-funding environment has been challenging per public industry data).
What china pharma spending adds to the risk case is that what china pharma spending adds to the risk case is that what china pharma spending adds to the risk case is that china-pharma analytical-instrument spending has been pressured by VBP and anti corruption policy dynamics per public industry communications.
Wyatt and BD BS Integration is worth tracking because wyatt and BD BS Integration is worth tracking because wyatt and BD BS Integration is worth tracking because integration execution affects acquisition-driven revenue growth.
The filing points to a cluster of risks around Wyatt and BD BS Integration and execution pressure rather than one neat red flag. A modest miss around Wyatt and BD BS Integration can still show up in margins and cash faster than investors expect. The balance sheet adds its own watch item because goodwill is 28.5% of assets and keeps attention on LC-MS Platform-related follow-through. What matters most from here is whether the existing economics can hold through the next turn in demand.
Management
Ask about this section
This analysis is for educational purposes only and does not constitute investment advice.